ClinicalTrials.gg
CompletedNCT04720716Updated Mar 19, 2026

A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC

A Phase 3 interventional study of IBI310 and Sintilimab in Hepatocellular Carcinoma, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-19.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
344
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 1,312 studies in Carcinoma, Hepatocellular with a site in China — 488 open to participants now, 560 under way, 70 of them phase 3. Carcinoma, Hepatocellular · China.

Enrollment
114th of 1,035
344 · median 78
Started
2021
with 116 others
Phase 3
169 of 1,312
40 open now
Registered
564th of 1,312
by date

Among the 1,312 studies in Carcinoma, Hepatocellular with a site in China, this one is the 114th largest by enrollment of the 1,035 interventional ones that give a count, is one of 117 that started in 2021, is one of 169 in phase 3, and was the 564th registered.

Carcinoma, Hepatocellular

3,652 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,065 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

488 of the 1,312 studies in Carcinoma, Hepatocellular with a site in China are open now. Recruiting first, the newest first:

483 more — sign in →

All 488 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 741 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 251 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,312 studies in Carcinoma, Hepatocellular with a site in China, or all of them as a file.
02

Study summary

This is a randomized, open-label, controlled, multicenter Phase III study to evaluate the effectiveness and safety of IBI310 combined with sintilimab and sorafenib in patients with locally advanced or metastatic HCC who have not previously received systemic therapy, are unsuitable for radical surgical resection or local treatment, or have had progressive disease after surgical resection or local treatment.

03

Conditions studied

  • Hepatocellular Carcinoma
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Histologically/ confirmed hepatocellular carcinoma, or liver cirrhosis meeting the clinical diagnostic criteria;
  2. performance status score of 0 or 1 point;
  3. No systemic antitumor treatment for hepatocellular carcinoma before the first administration;
  4. Barcelona Clinic Liver Cancer stage C, or Stage B not suitable for radical surgery and/or local treatment;
  5. At least 1 according to V1.1);
  6. :≤6
  7. Adequate organ and bone marrow function.

Exclusion criteria

Exclusion Criteria:

  1. With fibrous lamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, cholangiocarcinoma components in tumor tissues.
  2. Have a history of hepatic encephalopathy or have a history of liver transplantation.
  3. With clinical symptoms requires drainage of pleural effusion, ascites or pericardial effusion.
  4. Central nervous system (CNS) .
  5. Uncontrolled high blood pressure, systolic blood pressure >140mmHg or diastolic blood pressure >90mmHg after optimal medical treatment.
  6. Local treatment for liver lesions within 4 weeks.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
344 participants (actual)

Study arms

  • Experimental
    Sintilimab combined with IBI310

    Drug: IBI310 · Drug: Sintilimab

  • Active comparator
    Sorafenib

    Drug: Sorafenib

Interventions

06

What researchers measure

Primary outcomes

  1. Overall survival (OS)

    Time frame: up to 24 months after randomization

  2. Objective response rate (ORR)

    Objective response rate (ORR) in two arms based on RECIST V1.1 by the IRRC

    Time frame: up to 24 months after randomization

Secondary outcomes

  1. Progression-free survival (PFS)

    Progression-free survival (PFS) in two arms based on RECIST V1.1 by the IRRC and investigator

    Time frame: up to 24 months after randomization

  2. Duration of response(DOR)

    Duration of response(DOR) in two arms based on RECIST V1.1 by the IRRC and investigator

    Time frame: up to 24 months after randomization

  3. Disease control rate(DCR)

    Disease control rate(DCR) in two arms based on RECIST V1.1 by the IRRC and investigator

    Time frame: up to 24 months after randomization

  4. Time to progression(TTP)

    Time to progression(TTP) in two arms based on RECIST V1.1 by the IRRC and investigator

    Time frame: up to 24 months after randomization

  5. Time to response(TTR)

    Time to response(TTR) in two arms based on RECIST V1.1 by the IRRC and investigator

    Time frame: up to 24 months after randomization

  6. The incidence and severity of Treatment-Emergent Adverse Events

    Time frame: up to 24 months after randomization

07

Study locations

1 site
  • Fudan Universtiy Zhongshan Hospital
    Shanghai, Shanghai Municipality 200000, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Dec 2025, 58 months.

Of 53 industry-sponsored phase 3 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 63. This study's 58 months is close to that.

Counting every sponsor, half of 139 studies reached it within 56 months; a quarter within 43 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2021
First posted
Jan 22, 2021
StartActual
Feb 7, 2021
Primary completionActual
Dec 31, 2025
CompletionActual
Dec 31, 2025
Last update
Mar 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04720716
Responsible party
Sponsor
First posted
Jan 22, 2021
Start date
Feb 7, 2021
Primary completion
Dec 31, 2025
Completion
Dec 31, 2025
Last update
Mar 19, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-CTLA-4 Monoclonal Antibody IBI310

Start the discussion